GlobeNewswire: PLx Pharma Inc. Contains the last 10 of 92 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T11:54:38ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2023/04/12/2645780/0/en/PLx-Pharma-Inc-Enters-into-a-Stalking-Horse-Asset-Purchase-Agreement-to-Sell-VAZALORE-and-Substantially-All-of-its-Assets.html?f=22&fvtc=4&fvtv=31509PLx Pharma Inc. Enters into a Stalking Horse Asset Purchase Agreement to Sell VAZALORE® and Substantially All of its Assets2023-04-12T21:24:09Z<![CDATA[SPARTA, N.J., April 12, 2023 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ and VAZALORE®, an FDA-approved liquid-filled aspirin capsule, available in 81 mg and 325 mg doses. The Company today announced that it entered into a stalking horse asset purchase agreement (the “APA”) with PLx Acquisition Company, LLC, a wholly-owned subsidiary of Greenwood Brands, LLC (“Buyer”), to acquire substantially all of the Company’s assets (the “Sale”).]]>https://www.globenewswire.com/news-release/2023/04/11/2644951/0/en/PLx-Pharma-Inc-Receives-Nasdaq-Delisting-Notice.html?f=22&fvtc=4&fvtv=31509PLx Pharma Inc. Receives Nasdaq Delisting Notice2023-04-11T20:28:31Z<![CDATA[SPARTA, N.J., April 11, 2023 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the potential to improve the absorption of many drugs currently on the market and to reduce the risk of stomach injury associated with certain drugs. The Company had previously announced that on October 3, 2022, it was notified by the Listing Qualifications Department (the “Listing Qualifications Department”) of the Nasdaq Stock Market LLC (“Nasdaq”) that the Listing Qualifications Department has determined to delist the Company’s securities from Nasdaq, citing that for a period of 30 consecutive business days, the bid price of its common stock had closed below the minimum of $1.00 per share required for continued listing on Nasdaq pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Rule”). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company was provided 180 calendar days, or until April 3, 2023, to regain compliance with the minimum bid requirement. On April 4, 2023, the Company received notice from Nasdaq (the “April Notice”) indicating that the Company had not regained compliance with the Rule and is not eligible for a second 180-day period. The April Notice also stated that the Company had not yet filed its Form 10-K for the period ended December 31, 2022, meaning that the Company no longer complies with Nasdaq Listing Rule 5250(c)(1).]]>https://www.globenewswire.com/news-release/2022/11/10/2553883/0/en/PLx-Pharma-Inc-Reports-Third-Quarter-2022-Results-and-Provides-Business-Update.html?f=22&fvtc=4&fvtv=31509PLx Pharma Inc. Reports Third Quarter 2022 Results and Provides Business Update2022-11-10T22:00:00Z<![CDATA[- Significant Reduction in Operating Expenses]]>https://www.globenewswire.com/news-release/2022/10/26/2541885/0/en/PLx-Pharma-Inc-to-Report-Third-Quarter-2022-Financial-Results-on-November-11-2022-and-Provide-Business-Update.html?f=22&fvtc=4&fvtv=31509PLx Pharma Inc. to Report Third Quarter 2022 Financial Results on November 11, 2022, and Provide Business Update2022-10-26T13:00:00Z<![CDATA[SPARTA, N.J., Oct. 26, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”) is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the potential to improve the absorption of many drugs currently on the market and to reduce the risk of stomach injury associated with certain drugs. The Company, with its lead products VAZALORE 81 mg and VAZALORE 325 mg liquid-filled aspirin capsules (referred to together as “VAZALORE®”), today announced that it will release its third quarter 2022 financial results before the open of the U.S. financial markets on Friday, November 11, 2022.]]>https://www.globenewswire.com/news-release/2022/09/12/2514504/0/en/Baseball-Legend-John-Smoltz-Featured-on-PLx-Pharma-s-Social-Channels.html?f=22&fvtc=4&fvtv=31509Baseball Legend John Smoltz Featured on PLx Pharma’s Social Channels2022-09-12T20:30:00Z<![CDATA[Legendary Baseball Pitcher and Avid Golfer Uses VAZALORE® 325 mg for Fast, Effective Pain Relief Legendary Baseball Pitcher and Avid Golfer Uses VAZALORE® 325 mg for Fast, Effective Pain Relief]]>“From baseball to golf, I don’t want aches and pain to slow me down,” said Smoltz. “VAZALORE is the only pain reliever I have found that works quickly on my aches and pains and doesn’t upset my stomach.”Legendary Baseball Pitcher and Avid Golfer John Smoltz Uses VAZALORE 325 mg For Fast, Effective Pain Reliefhttps://www.globenewswire.com/news-release/2022/08/12/2497479/0/en/Survey-Cardiovascular-Patients-on-Aspirin-Therapy-Prefer-VAZALORE-81-mg.html?f=22&fvtc=4&fvtv=31509Survey: Cardiovascular Patients on Aspirin Therapy Prefer VAZALORE® 81 mg2022-08-12T11:00:00Z<![CDATA[Results of National Patient Experience Survey Show 95% Satisfaction Rate]]>The First and Only Liquid-Filled Aspirin CapsulesVAZALORE 81 mg Low-Dose Liquid-Filled Aspirin Capsuleshttps://www.globenewswire.com/news-release/2022/08/12/2497463/0/en/PLx-Pharma-Inc-Reports-Second-Quarter-2022-Results-and-Provides-Business-Update.html?f=22&fvtc=4&fvtv=31509PLx Pharma Inc. Reports Second Quarter 2022 Results and Provides Business Update2022-08-12T10:50:00Z<![CDATA[- Initiates Evaluation of Strategic Alternatives to Enhance Stockholder Value]]>https://www.globenewswire.com/news-release/2022/07/27/2486876/0/en/PLx-Pharma-Inc-to-Report-Second-Quarter-2022-Financial-Results-August-12-2022-and-Provide-Business-Update.html?f=22&fvtc=4&fvtv=31509PLx Pharma Inc. to Report Second Quarter 2022 Financial Results August 12, 2022, and Provide Business Update2022-07-27T12:30:00Z<![CDATA[SPARTA, N.J., July 27, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”) is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the potential to improve the absorption of many drugs currently on the market and to reduce the risk of stomach injury associated with certain drugs. The Company, with its lead products VAZALORE 81 mg and VAZALORE 325 mg liquid-filled aspirin capsules (referred to together as “VAZALORE®”), today announced that it will release its second quarter 2022 financial results before the open of the U.S. financial markets on Friday, August 12, 2022.]]>https://www.globenewswire.com/news-release/2022/06/01/2454288/0/en/PLx-Pharma-Inc-to-Present-at-JMP-Securities-2022-Life-Sciences-Conference-on-June-15-2022.html?f=22&fvtc=4&fvtv=31509PLx Pharma Inc. to Present at JMP Securities 2022 Life Sciences Conference on June 15, 20222022-06-01T12:30:00Z<![CDATA[SPARTA, N.J., June 01, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”) is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the potential to improve the absorption of many drugs currently on the market and to reduce the risk of stomach injury associated with certain drugs. The Company, with its lead products VAZALORE 81 mg and VAZALORE 325 mg liquid-filled aspirin capsules (referred to together as “VAZALORE®”), today announced that Natasha Giordano, President and CEO and Rita O’Connor, Chief Financial Officer & Head of Manufacturing & Supply Chain, will present on June 15, 2022, at JMP Securities 2022 Life Sciences Conference in New York City.]]>https://www.globenewswire.com/news-release/2022/05/20/2447672/0/en/PLx-Pharma-Inc-Showcases-VAZALORE-at-The-Annual-Meeting-of-The-Society-for-Cardiovascular-Angiography-and-Interventions.html?f=22&fvtc=4&fvtv=31509PLx Pharma Inc. Showcases VAZALORE at The Annual Meeting of The Society for Cardiovascular Angiography and Interventions2022-05-20T12:30:00Z<![CDATA[VAZALORE Featured in Prominent Publication as Promising Alternative to Current Aspirin Options for Secondary Prevention of Cardiac Events VAZALORE Featured in Prominent Publication as Promising Alternative to Current Aspirin Options for Secondary Prevention of Cardiac Events]]>